Mylan (MYL) Receives FDA Approval for Generic Version of Takeda's Actoplus Met
- Facebook (FB) Tops Q2 EPS by 3c
- Market Wrap: Pending Sales Miss Views in June; FOMC Looks to Jobs for Rate Hike; Facebook Slumps on Mobile Results
- Whole Foods Market (WFM) Misses Q3 EPS by 1c, Sees FY15 Comp Sales Growth in Low Single Digits
- Fed sees improving economy, job market; September rate hike in view
- Twitter (TWTR) Sees Rollercoaster Ride Following Earnings, User Growth Commentary
Bloomberg reporting Mylan (NYSE: MYL) has won FDA approval for its generic version of Takeda's actoplus met.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mylan (MYL) Approved by European Commission to Acquire Perrigo (PRGO)
- Teva Pharma (TEVA) Ratings Cut to 'BBB+' by S&P; Remains on CreditWatch Negative
- Merck (MRK) to Acquire cCAM Biotherapeutics in ~$605M Deal
Create E-mail Alert Related CategoriesFDA, Rumors
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!